Related references
Note: Only part of the references are listed.Nonsteroidal Anti-Inflammatory Drugs and the Heart
Carlo Patrono et al.
CIRCULATION (2014)
GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
Byron Cryer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis
Isla S. Mackenzie et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications
Sam Harirforoosh et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2013)
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib
Magnus Back et al.
EUROPEAN HEART JOURNAL (2012)
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity
Philip G. Conaghan
RHEUMATOLOGY INTERNATIONAL (2012)
Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta-Analyses of Randomized Clinical Trials
F. Salvo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies
Luis Alberto Garcia Rodriguez et al.
PLOS ONE (2011)
Stroke risk and NSAIDs: a systematic review of observational studies
Cristina Varas-Lorenzo et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Sven Trelle et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Use of Non-Steroidal Antiinflammatory Drugs and Type-Specific Risk of Acute Coronary Syndrome
Hector Bueno et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users
David Laharie et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study
Bjorn Gudbjornsson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events
Jun-Yan Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Renal adverse effects of nonsteroidal anti-inflammatory drugs
Sam Harirforoosh et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Bernard Combe et al.
RHEUMATOLOGY (2009)
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
Roy Fleischmann et al.
BMC MUSCULOSKELETAL DISORDERS (2008)
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials - The cross trial safety analysis
Scott D. Solomon et al.
CIRCULATION (2008)
Pilot randomized phase II study of celecoxib in oral premalignant lesions
Vassiliki A. Papaclimitrakopoulou et al.
CLINICAL CANCER RESEARCH (2008)
Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke
Christianne L. Roumie et al.
STROKE (2008)
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)
K. Krueger et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups
Janet van Adelsberg et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer
David J. Kerr et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident
N. S. Abraham et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
C. O. Bingham et al.
RHEUMATOLOGY (2007)
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease Anti-inflammatory Prevention Trial (ADAPT)
Barbara K. Martin et al.
PLOS CLINICAL TRIALS (2006)
Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent
Sam Harirforoosh et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Celecoxib for the prevention of colorectal adenomatous polyps
Nadir Arber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study
G Singh et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone
AL Weaver et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2006)
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis - Results of a fifty-two-week, randomized, controlled study
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cyclo-oxygenase-1 and-2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance
M Shibata et al.
ORAL ONCOLOGY (2005)
Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat
S Harirforoosh et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2005)
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib - Interim results from the New Zealand intensive medicines monitoring programme
M Harrison-Woolrych et al.
DRUG SAFETY (2005)
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein - A randomized placebo-controlled study
P Bogaty et al.
CIRCULATION (2004)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
ME Farkouh et al.
LANCET (2004)
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
TD Warner et al.
FASEB JOURNAL (2004)
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis - A randomized, controlled trial
JR Lisse et al.
ANNALS OF INTERNAL MEDICINE (2003)
Comparison of thromboembolic events in patients treated with Celecoxib, a cyclooxygenase-1 specific inhibitor, versus Ibuprofen or Diclofenac
WB White et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetane)
AS Reicin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Adverse gastrointestinal effects of NSAIDs: consequences and costs
M Bidaut-Russell et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2001)
Epidemiology of NSAID-related gastroduodenal mucosal injury
C Aalykke et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2001)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial
FE Silverstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
